Post ASCO GU ’22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC Patients

Oncology News Central Peer-Spectives
07/03/2022 9 min
Post ASCO GU ’22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC Patients

Listen "Post ASCO GU ’22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC Patients"

Descargar episodio Ver en sitio original

Episode Synopsis

Daniel Petrylak, MD, Professor of Medicine at the Yale Cancer Center, and Robert Figlin, MD, of Cedars-Sinai Cancer discuss recent developments at ASCO GU in muscle-invasive bladder cancer and in particular the EV-103 clinical study while also discussing the future of MIBC treatment.

More episodes of the podcast Oncology News Central Peer-Spectives

Should Patients With Cancer Receive mRNA Vaccines Alongside Immunotherapy? 21/11/2025
Big News From ESMO 2025 Changes Practice in Bladder Cancer 30/10/2025
Big Changes in AML Care as Targeted Therapy Options Expand 20/10/2025
Artificial Sweetener May Impair Cancer Immunotherapy, Raising Broader Questions 22/09/2025
“Massive Advance” Changes the Chessboard in EGFR-Mutated Metastatic NSCLC 16/09/2025
Are Oral SERDs About to Transform Breast Cancer Care? 15/07/2025
Game-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer Care 14/07/2025
Practice-Changing Data in Colorectal Cancer Lead to Broader Questions in Oncology 11/07/2025
Oncologist Faculty Burnout Caused by “Unrealistic” Expectations, Says ASCO CEO 08/07/2025
After Years of Inactivity, “Dizzying” Changes Hit Bladder Cancer Care 07/07/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA